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Abstract: Introduction: Migraine is a common cause of emergency department (ED) visits. To date, there is no recom-
mended drug of choice for pain management of these patients. In the present study, we aimed to evaluate the
effectiveness of ketorolac and magnesium sulfate in this regard. Methods: This is a cross-sectional study per-
formed on all 18 - 60 year-old patients, visiting two different EDs with complaint of moderate to severe migraine
headache. Patients were treated with 30 mg ketorolac in one hospital and 1 gram magnesium sulfate in the other.
Pain scores were assessed on arrival, 1 and 2 hours after drugs administration and quality of pain management
was compared between two groups using SPSS 22. Results: 70 patients with the mean age of 36.4 ± 11.4 years
were enrolled (51.4% male). The two groups were similar regarding baseline characteristics (p > 0.05). The im-
provement in pain score in magnesium sulfate group was greater than Ketorolac group after both one hour (6
vs 3; p < 0.001) and two hours (7 vs 5; p < 0.001). Conclusion:It seems that both ketorolac and magnesium sul-
fate are significantly effective in pain control of patients with migraine headache presenting to the emergency
department. Magnesium sulfate was superior to ketorolac both one and two hours after drug administration.
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1. Introduction
Migraine is a disabling disorder and a common cause of
emergency department (ED) visits (1, 2). Migraine preva-
lence has been reported to be 12-20% in different popula-
tions (3). To date, various drugs such as opium, nonsteroidal
anti-inflammatory drugs (NSAIDs), neuroleptics, and trip-
tans have been used for treatment of migraine headaches in
ED (4-7). Numerous studies have been carried out to evalu-
ate the effectiveness of above-mentioned drugs, but to date
there is no recommended drug of choice for this purpose.
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Magnesium sulfate and NSAIDs such as ketorolac are among
the common drugs used for migraine headache pain man-
agement (8-14). In the present study, we aimed to evaluate
the effectiveness of ketorolac and magnesium sulfate in con-
trolling migraine headaches in patients presented to ED.
2. Materials and methods
2.1. Study design and settings
This is a cross-sectional study performed from April to Oc-
tober 2015 in emergency departments of Imam Hossein and
Shohadaye Tajrish Hospitals, Tehran, Iran, to compare the ef-
fectiveness of ketorolac and magnesium sulfate in migraine
pain management.
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2.2. Ethical issues
The protocol of the study was approved by the Ethical Com-
mittee of Shahid Beheshti University of Medical Sciences.
The authors declare their adherence to ethical principles of
Helsinki Declaration throughout this research. Eligible pa-
tients were enrolled after signing informed consent form.
2.3. Participant
All 18 - 60 year-old patients, visiting the emergency depart-
ment with complaint of moderate to severe headache were
interviewed by the main investigators. They were included
if compatible with the international headache society (IHS)
criteria for common migraine and had a pain score more
than 5 (based on visual analogue scale (VAS)). Patients with
history of peptic ulcer disease, ischemic heart disease, in-
flammatory bowel disease, coagulopathy, renal or hepatic
failure, history of recent major surgery, history of hypersensi-
tivity to the studied drug, and hypertension, as well as preg-
nant or breastfeeding women were excluded.
2.4. Studied groups
Patients in Shohadaye Tajrish Hospital were treated with 30
milligrams ketorolac and those in Imam Hossein Hospital
with 1 gram magnesium sulfate. One of the investigators
in each hospital assessed pain scores on arrival, 1 and 2
hours after drug administration, when plasma concentration
reaches its peak level. Patients, pain investigator, and data
analyzer were blind to the administered treatment. 3 or more
scores decrease in VAS was considered as clinically signifi-
cant pain management.
2.5. Statistical analysis
Statistical analysis was performed using SPSS version 22.
Continuous variables were described as mean ± standard
deviation, and categorical ones as median, interquartile
range, frequency and percentage. Mann-Whitney U test and
Wilcoxon test were used to analyze differences in VAS pain
scores. P value < 0.05 was considered significant.
3. Results
Seventy patients with the mean age of 36.4 ± 11.4 years were
enrolled (51.4% male). Baseline characteristics of patients in
each group, as well as their VAS scores at baseline, 1 hour, and
2 hours after drug administration are compared in table and
figure 1. The improvement in VAS pain score in magnesium
sulfate group was greater than Ketorolac group after both one
hour (6 vs 3; p < 0.001) and two hours (7 vs 5; p < 0.001).
Figure 1: Box plot comparing minimum, maximum, median and
inter-quartile range of pain scores at baseline, 1 hour, and 2 hours
after drug administration between ketorolac and magnesium sulfate
groups (p < 0.001).
4. Discussion
Based on data extracted from the current study, both ketoro-
lac and magnesium sulfate are significantly effective in pain
control of patients with migraine headache presenting to the
ED. Magnesium sulfate was superior to ketorolac one and
also two hours after drug administration. These drugs have
been studied in patients with migraine headache solely or in
comparison with other drugs. However, searching in Google
Scholar and Pubmed database with ”ketorolac and magne-
sium sulfate and migraine” as keywords, did not find any ar-
ticle that compared these two with each other. The findings
of the literature have yielded conflicting results. A paper re-
view performed in 2000 on the effectiveness and safety of
different therapies in migraine headache, revealed that mag-
nesium sulfate needs to be studied in appropriate trials be-
fore a conclusions can be drawn. Ketorolac performs a little
better but has been shown to be inferior to other treatments
(15). 15 years later in 2015, based on published literatures be-
tween 1998 and 2013, American Headache Society reported
that both ketorolac and magnesium sulfate are probably ef-
fective for acute migraine treatment (Level B evidence) (16).
Simultaneously, Canadian Headache Society strongly recom-
mended the use of ketorolac, based on a low level of evidence
and weakly recommended against the use of magnesium sul-
fate, based on moderate-quality evidence (17). High quality
papers that have been published recently in authentic jour-
nals, clarify the ambiguity surrounding this topic. The cur-
rent study still cannot prove anything with high reliability;
but can be considered as a pilot study for running further ap-
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Table 1: Baseline characteristics of the patients in the two groups
Variables Ketorolac Magnesium sulfate P
Age; mean ± SD 36.9 ± 10.7 36.0 ± 12.5 0.73
Gender; male number (%) 15 (42.9) 19 (54.3%) 0.33
Analgesic consumption before arrival; number (%) 18 (51.4) 12 (34.3) 0.14
Duration of analgesic consumption before arrival; mean ± SD (hour) 3.0 ± 2.08 3.4 ± 1.6 0.56
Pain score on arrival; median (IQR) 8 (3) 8 (2) 0.15
Pain score after 1 hour; median (IQR) 4 (4) 2 (2) <0.001
Pain score after 2 hours; median (IQR) 3 (2) 0 (1) <0.001
SD: standard deviation, IQR: inter quartile range.
propriate double blind randomized controlled trials.
5. Conclusion
It seems that both ketorolac and magnesium sulfate are sig-
nificantly effective in pain control of patients with migraine
headache presenting to the emergency department. Mag-
nesium sulfate was superior to ketorolac both one and two
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